[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367476-105":59,"doc-detail-367476-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hpv-driven-cancers-a-looming-threat-and-the-potential-of-crisprcas9-for-targeted-therapy","HPV-driven cancers - a looming threat and the potential of CRISPR/Cas9 for targeted therapy","","Cervical and other anogenital malignancies are largely driven by E6 and E7 oncogenes from high-risk human papillomaviruses (HPVs), which persistently suppress tumor suppressors such as p53 and pRb. Traditional treatments often provide only temporary relief, carry significant side effects, and show high recurrence risk. This review evaluates CRISPR-Cas9 gene editing to both induce death in HPV-infected cancer cells and reactivate tumor suppressor pathways. It emphasizes guide RNAs targeting integrated HPV DNA, restart of natural apoptotic processes, and the need for future trials to establish therapeutic value.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hpv-driven-cancers-a-looming-threat-and-the-potential-of-crisprcas9-for-targeted-therapy/367476/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hpv-driven-cancers-a-looming-threat-and-the-potential-of-crisprcas9-for-targeted-therapy/367476.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do HPV E6 and E7 contribute to cancer development?","Question",{"text":113,"@type":114},"High-risk HPV E6 and E7 are persistently expressed and inhibit key tumor suppressors such as p53 and pRb, leading to uncontrolled cell division and malignant transformation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are traditional treatments insufficient for HPV-driven cancers?",{"text":118,"@type":114},"Current ablative or cytodestructive therapies can clear lesions in the short term, but recurrence remains substantial, and invasive nonspecific approaches such as chemotherapy, radiation, and surgery add serious side effects.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the proposed role of CRISPR/Cas9 in targeted therapy?",{"text":122,"@type":114},"CRISPR-Cas9 is proposed to create guide RNAs that target integrated HPV DNA, inhibiting E6/E7 effects while reactivating p53 and pRb to halt aberrant development and restart natural dying pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367476,1790431561,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Kermanshahi etal. Virology Journal (2025) 22:156  \n[https://doi.org/10.1186/s12985-025-02783-x](https://doi.org/10.1186/s12985-025-02783-x)  \nVirology Journal  \nREVIEW Open Access  \nHPV-driven cancers: a looming threat and the potential of CRISPR/Cas9 for targeted therapy  \nAtefeh Zamani Kermanshahi 1,2†, Fatemeh Ebrahimi 1,4†, Ahmad Taherpoor5, Narges Eslami6,7 and Hossein Bannazadeh Baghi 1,2,3*  \nAbstract  \nCervical and other anogenital malignancies are largely caused by E6 and E7 oncogenes of high-risk human papillomaviruses (HPVs), which inhibit important tumor suppressors like p53 and pRb when they are persistently activated. The main goal of traditional treatments is to physically or chemically kill cancer cells, but they frequently only offer temporary relief, have serious side effects, and have a high risk of recurrence. Exploring the efficacy and accuracy of CRISPR-Cas9 gene editing in both inducing death in HPV-infected cancer cells and restoring the activity of tumor suppressors is our main goal. In this study, we propose a novel precision oncology strategy that targets and inhibits the detrimental effects of the E6 and E7 oncogenes using the CRISPR-Cas9 gene editing system. In order to do this, we create unique guide RNAs that target the integrated HPV DNA and reactivate p53 and pRb. Reactivation is meant to halt aberrant cell development and restart the cell’s natural dying pathways. This review discusses the potential of CRISPR/Cas9 in targeting HPV oncogenes, with a focus on studies that have demonstrated its promise in cancer treatment. Given the absence of a definitive treatment for papillomavirus infection and its subsequent association with various cancers, future clinical trials and experimental investigations appear essential to establish and evaluate the therapeutic potential of CRISPR-based approaches. This approach provides a less invasive alternative to conventional treatments and opens the door to personalized care that considers the genetic makeup of each patient’s tumor.  \nKeywords HPV, CRISPR-Cas9, Gene editing, Oncogenes, Tumor suppressors  \n†Atefeh Zamani Kermanshahi and Fatemeh Ebrahimi contributed equally to this work.  \n*Correspondence:  \nHossein Bannazadeh Baghi  \n[hbannazadeh@tbzmed.ac.ir](hbannazadeh@tbzmed.ac.ir); [hb.zadeh@gmail.com](hb.zadeh@gmail.com)  \n1Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 5166/15731, Iran  \n2Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran  \n3Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran  \n4Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran  \n5Department of Clinical Bacteriology; Virology, Faculty of Medicine and Anti-microbial Research Center, Mashhad University of Medical Sciences, Mashhad, Iran  \n6Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran  \n7Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you wil","cbCaicUcrPbm1V7H","https://ap.wps.com/l/cbCaicUcrPbm1V7H","pdf",1340204,17,"English","# Introduction\n## HPV-driven malignancies and E6/E7 oncogenes\n## Limitations of current treatments and need for targeted approaches\n## Emerging strategies including immunotherapy and RNA-based therapies\n# Review focus: CRISPR/Cas9 for targeted therapy\n## Rationale for guide RNAs against integrated HPV DNA\n## Reactivation of p53 and pRb and restoration of apoptosis pathways\n## Translational outlook and future clinical trials","[{\"question\":\"How do HPV E6 and E7 contribute to cancer development?\",\"answer\":\"High-risk HPV E6 and E7 are persistently expressed and inhibit key tumor suppressors such as p53 and pRb, leading to uncontrolled cell division and malignant transformation.\"},{\"question\":\"Why are traditional treatments insufficient for HPV-driven cancers?\",\"answer\":\"Current ablative or cytodestructive therapies can clear lesions in the short term, but recurrence remains substantial, and invasive nonspecific approaches such as chemotherapy, radiation, and surgery add serious side effects.\"},{\"question\":\"What is the proposed role of CRISPR/Cas9 in targeted therapy?\",\"answer\":\"CRISPR-Cas9 is proposed to create guide RNAs that target integrated HPV DNA, inhibiting E6/E7 effects while reactivating p53 and pRb to halt aberrant development and restart natural dying pathways.\"}]","HPV-driven cancers - a looming threat and the potential of CRISPR/Cas9 for targeted therapy | PDF",1790170978,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8920eba90b534af60835b65328dbb516.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74000168a0e4ab12bf2bc7b74571df78.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/234b077e42cdb10559283ce120977bb7.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa902bf170b6f95a196323f62aa52b4b.webp",980,1306]